Tirzepatide Dosing and Administration

Standard Dosing Protocol

The FDA-approved dosing range for tirzepatide includes 5 mg, 10 mg, and 15 mg weekly, as recommended by the American Diabetes Association 1, 2
Tirzepatide is administered as a subcutaneous injection once weekly, with a recommended dose escalation strategy starting at lower doses and gradually increasing to minimize gastrointestinal side effects, as suggested by the American Medical Association 3, 4
The 15 mg dose provides the maximum efficacy with 20.9% weight loss at 72 weeks in patients with obesity, compared to 19.5% with 10 mg and 15.0% with 5 mg, according to the American College of Cardiology 3, 4

No dose adjustment is necessary for patients with mild to moderate renal impairment, as stated by the American Society of Anesthesiologists 5, 6
For perioperative management, consider stopping tirzepatide before elective procedures due to its effect on gastric emptying, as recommended by the American Society of Anesthesiologists 5
During Ramadan fasting, tirzepatide can be continued at the established dose, with some experts recommending reaching at least the 7 mg dose 2-3 weeks before Ramadan begins, according to the European Association for the Study of Diabetes 7

Assess effectiveness and safety at least monthly for the first 3 months and at least quarterly thereafter, as suggested by the American Diabetes Association 1
Monitor for gastrointestinal side effects, which are the most common adverse events, including nausea (13-18%) 1
Tirzepatide may delay gastric emptying, which could affect the absorption of oral medications with narrow therapeutic indices, as noted by the American Diabetes Association and the American Society of Anesthesiologists 1, 5

For patients using oral hormonal contraception, advise using or adding a non-oral contraception method for 4 weeks after initiation and dose escalations, as recommended by the American College of Obstetricians and Gynecologists 2

When increasing from 5 mg to 10 mg of tirzepatide, patients may experience an increased incidence of gastrointestinal side effects, including nausea, constipation, diarrhea, and decreased appetite, with constipation occurring in 12-18% of patients 8
The American Society of Anesthesiologists notes that common side effects of tirzepatide dose escalation include constipation, occurring in 12-18% of patients, and diarrhea, occurring in 12-17% of patients 8
Decreased appetite is also a common side effect, occurring in 10-12% of patients, according to the Anaesthesia journal 8